Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric eliglustat study in Gaucher disease type 1 and type 3
2024-510751-34-00Phase 3Completed
- Sponsor
- Sanofi
- Start
- Apr 2024
- Modality
- Small Molecules, Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, open-label trial of eliglustat and imiglucerase in Gaucher disease type 1 (GD1) and Gaucher disease type 3 (2 arms), sponsored by Sanofi. Primary endpoints: Assessment of pharmacokinetic parameter of eliglustat: Cmax, Assessment of pharmacokinetic parameter of eliglustat: AUC and 1 more. Started Apr 2024; status: completed.
02
Drugs
eliglustatimiglucerase
03
Conditions
Gaucher disease type 1 (GD1)Gaucher disease type 3
Beyond the preview
Go deeper on 2024-510751-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510751-34-00.